Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Clinical trial NCT04280848 · COMPLETED
Trial details
- NCT number
- NCT04280848
- Sponsor
- Centre Hospitalier Universitaire de Besancon
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-26
- Primary completion
- 2023-12-21
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.